Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | VDR | P11473 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23643337 | 0.79 | RECQL (0.35) | RECQLVDRGAA | |
| SCHEMBL20802464 | 0.79 | MEN1 (0.46) | RECQLVDRGAA | |
| SCHEMBL19323273 | 0.77 | HPGD (0.42) | RECQLGAA | |
| SCHEMBL3467454 | 0.77 | ALDH1A1 (0.44) | RECQLVDRGAA | |
| SCHEMBL12617509 | 0.77 | TERT (0.38) | RECQLVDRGAA | |
| SCHEMBL21850085 | 0.76 | CA1 (0.34) | RECQLVDR | |
| SCHEMBL8056854 | 0.76 | RECQL (0.33) | RECQLVDR | |
| SCHEMBL22345261 | 0.74 | RECQL (0.61) | RECQLGAA | |
| SCHEMBL21099972 | 0.74 | RECQL (0.55) | RECQLGAA | |
| SCHEMBL4742448 | 0.74 | RECQL (0.41) | RECQLGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741018-A2 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2026-05-13 | — | — | EP | disclosed |
| EP-4739680-A1 | SOLID FORMS OF TRPV4 ANTAGONISTS | Actio Biosciences, Inc. (US) | 2026-05-13 | — | — | EP | disclosed |
| US-12583836-B2 | Sulphonamide compounds | Anaxis Pharma Pty Ltd (AU) | 2026-03-24 | — | — | US | disclosed |
| EP-4168401-B1 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2026-01-07 | — | — | EP | disclosed |
| US-20250333403-A1 | THERAPEUTIC COMPOUNDS AND METHODS | ACTIO BIOSCIENCES INC (US) | 2025-10-30 | — | — | US | disclosed |
| US-12391683-B2 | Therapeutic compounds and methods | ACTIO BIOSCIENCES, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| EP-4551572-A1 | THERAPEUTIC COMPOUNDS AND METHODS | Actio Biosciences, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| US-20250074891-A1 | BIFUNCTIONAL SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-03-06 | — | — | US | disclosed |
| WO-2025014818-A1 | SOLID FORMS OF GSK2798745, A TRPV4 ANTAGONIST | ACTIO BIOSCIENCES, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| EP-4452966-A1 | BIFUNCTIONAL SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023115149-A1 | BIFUNCTIONAL SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| EP-4168401-A1 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-04-26 | — | — | EP | disclosed |
| CN-115956070-A | Sulfonamide compounds | 阿纳克西斯制药股份有限公司 | 2023-04-11 | — | — | CN | disclosed |
| WO-2021253095-A1 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2021-12-23 | — | — | WO | disclosed |
| US-20200251667-A1 | MONOSUBSTITUTED DIAZABENZIMIDAZOLE CARBENE METAL COMPLEXES FOR USE IN ORGANIC LIGHT EMITTING DIODES | UDC IRELAND LTD (IE) | 2020-08-06 | — | — | US | disclosed |
| EP-3608329-A1 | MONOSUBSTITUTED DIAZABENZIMIDAZOLE CARBENE METAL COMPLEXES FOR USE IN ORGANIC LIGHT EMITTING DIODES | UDC Ireland Limited (IE) | 2020-02-12 | — | — | EP | disclosed |
| EP-3266789-B1 | MONOSUBSTITUTED DIAZABENZIMIDAZOLE CARBENE METAL COMPLEXES FOR USE IN ORGANIC LIGHT EMITTING DIODES | UDC IRELAND LTD (IE) | 2019-09-25 | — | — | EP | disclosed |
| EP-3016960-B1 | MONOSUBSTITUTED DIAZABENZIMIDAZOLE CARBENE METAL COMPLEXES FOR USE IN ORGANIC LIGHT EMITTING DIODES | UDC IRELAND LTD (IE) | 2017-04-26 | — | — | EP | disclosed |
| US-20160372687-A1 | MONOSUBSTITUTED DIAZABENZIMIDAZOLE CARBENE METAL COMPLEXES FOR USE IN ORGANIC LIGHT EMITTING DIODES | BASF SE (DE) | 2016-12-22 | — | — | US | disclosed |
| WO-2015000955-A1 | MONOSUBSTITUTED DIAZABENZIMIDAZOLE CARBENE METAL COMPLEXES FOR USE IN ORGANIC LIGHT EMITTING DIODES | BASF SE (DE) | 2015-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250333403-A1 | THERAPEUTIC COMPOUNDS AND METHODS | TRPV4, TRPV3, TRPV2 | RECQL 2226/4885TRPA1 8/4885VDR 274/4885 |
| US-20250074891-A1 | BIFUNCTIONAL SULPHONAMIDE COMPOUNDS | MLKL, RIPK3, CASP9 | RECQL 4370/4885TRPA1 2181/4885VDR 4274/4885 |
| US-12583836-B2 | Sulphonamide compounds | MLKL, RIPK3, CASP1 | RECQL 4220/4885TRPA1 2336/4885VDR 1898/4885 |
| US-20200251667-A1 | MONOSUBSTITUTED DIAZABENZIMIDAZOLE CARBENE METAL COMPLEXES FOR USE IN ORGANIC LIGHT EMITTING DIODES | DDT, OCIAD1, OCIAD2 | RECQL 4390/4885TRPA1 75/4885VDR 118/4885 |
| US-12391683-B2 | Therapeutic compounds and methods | TRPV4, TRPV3, TRPV2 | RECQL 2226/4885TRPA1 8/4885VDR 274/4885 |
| US-20160372687-A1 | MONOSUBSTITUTED DIAZABENZIMIDAZOLE CARBENE METAL COMPLEXES FOR USE IN ORGANIC LIGHT EMITTING DIODES | DDT, OCIAD1, OCIAD2 | RECQL 4390/4885TRPA1 75/4885VDR 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.